Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Gastrointestinal Cancer Drugs Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Oncology
  • 1.3.3 Radiology
  • 1.3.4 Others
• 1.4 Market Segment by Application
  • 1.4.1 Global Gastrointestinal Cancer Drugs Market Share by Application (2019-2025)
  • 1.4.2 Hospitals
  • 1.4.3 Specialized Cancer Treatment Centers
  • 1.4.4 Clinics
  • 1.4.5 Ambulatory Surgical Centers
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Gastrointestinal Cancer Drugs Market Size
  • 2.1.1 Global Gastrointestinal Cancer Drugs Revenue 2014-2025
  • 2.1.2 Global Gastrointestinal Cancer Drugs Sales 2014-2025
• 2.2 Gastrointestinal Cancer Drugs Growth Rate by Regions
  • 2.2.1 Global Gastrointestinal Cancer Drugs Sales by Regions 2014-2019
  • 2.2.2 Global Gastrointestinal Cancer Drugs Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Gastrointestinal Cancer Drugs Sales by Manufacturers
  • 3.1.1 Gastrointestinal Cancer Drugs Sales by Manufacturers 2014-2019
  • 3.1.2 Gastrointestinal Cancer Drugs Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Gastrointestinal Cancer Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Gastrointestinal Cancer Drugs Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Gastrointestinal Cancer Drugs Market Concentration Ratio (CR5 and HHI)
• 3.3 Gastrointestinal Cancer Drugs Price by Manufacturers
• 3.4 Key Manufacturers Gastrointestinal Cancer Drugs Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Gastrointestinal Cancer Drugs Market
• 3.6 Key Manufacturers Gastrointestinal Cancer Drugs Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Oncology Sales and Revenue (2014-2019)
  • 4.1.2 Radiology Sales and Revenue (2014-2019)
  • 4.1.3 Others Sales and Revenue (2014-2019)
• 4.2 Global Gastrointestinal Cancer Drugs Sales Market Share by Type
• 4.3 Global Gastrointestinal Cancer Drugs Revenue Market Share by Type
• 4.4 Gastrointestinal Cancer Drugs Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Gastrointestinal Cancer Drugs Sales by Application

6 United States

• 6.1 United States Gastrointestinal Cancer Drugs Breakdown Data by Company
• 6.2 United States Gastrointestinal Cancer Drugs Breakdown Data by Type
• 6.3 United States Gastrointestinal Cancer Drugs Breakdown Data by Application

7 European Union

• 7.1 European Union Gastrointestinal Cancer Drugs Breakdown Data by Company
• 7.2 European Union Gastrointestinal Cancer Drugs Breakdown Data by Type
• 7.3 European Union Gastrointestinal Cancer Drugs Breakdown Data by Application

8 China

• 8.1 China Gastrointestinal Cancer Drugs Breakdown Data by Company
• 8.2 China Gastrointestinal Cancer Drugs Breakdown Data by Type
• 8.3 China Gastrointestinal Cancer Drugs Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Gastrointestinal Cancer Drugs Breakdown Data by Company
• 9.2 Rest of World Gastrointestinal Cancer Drugs Breakdown Data by Type
• 9.3 Rest of World Gastrointestinal Cancer Drugs Breakdown Data by Application
• 9.4 Rest of World Gastrointestinal Cancer Drugs Breakdown Data by Countries
  • 9.4.1 Rest of World Gastrointestinal Cancer Drugs Sales by Countries
  • 9.4.2 Rest of World Gastrointestinal Cancer Drugs Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Amgen Limited & Amgen Ireland Limited
  • 10.1.1 Amgen Limited & Amgen Ireland Limited Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Gastrointestinal Cancer Drugs
  • 10.1.4 Gastrointestinal Cancer Drugs Product Introduction
  • 10.1.5 Amgen Limited & Amgen Ireland Limited Recent Development
• 10.2 Bristol-Myers Squibb Company
  • 10.2.1 Bristol-Myers Squibb Company Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Gastrointestinal Cancer Drugs
  • 10.2.4 Gastrointestinal Cancer Drugs Product Introduction
  • 10.2.5 Bristol-Myers Squibb Company Recent Development
• 10.3 F. Hoffmann-La Roche Ltd.
  • 10.3.1 F. Hoffmann-La Roche Ltd. Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Gastrointestinal Cancer Drugs
  • 10.3.4 Gastrointestinal Cancer Drugs Product Introduction
  • 10.3.5 F. Hoffmann-La Roche Ltd. Recent Development
• 10.4 Eli Lilly and Company
  • 10.4.1 Eli Lilly and Company Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Gastrointestinal Cancer Drugs
  • 10.4.4 Gastrointestinal Cancer Drugs Product Introduction
  • 10.4.5 Eli Lilly and Company Recent Development
• 10.5 Johnson & Johnson Private Limited
  • 10.5.1 Johnson & Johnson Private Limited Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Gastrointestinal Cancer Drugs
  • 10.5.4 Gastrointestinal Cancer Drugs Product Introduction
  • 10.5.5 Johnson & Johnson Private Limited Recent Development
• 10.6 GlaxoSmithKline plc.
  • 10.6.1 GlaxoSmithKline plc. Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Gastrointestinal Cancer Drugs
  • 10.6.4 Gastrointestinal Cancer Drugs Product Introduction
  • 10.6.5 GlaxoSmithKline plc. Recent Development
• 10.7 Celgene Corporation
  • 10.7.1 Celgene Corporation Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Gastrointestinal Cancer Drugs
  • 10.7.4 Gastrointestinal Cancer Drugs Product Introduction
  • 10.7.5 Celgene Corporation Recent Development
• 10.8 Pfizer Inc.
  • 10.8.1 Pfizer Inc. Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Gastrointestinal Cancer Drugs
  • 10.8.4 Gastrointestinal Cancer Drugs Product Introduction
  • 10.8.5 Pfizer Inc. Recent Development
• 10.9 Sanofi
  • 10.9.1 Sanofi Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Gastrointestinal Cancer Drugs
  • 10.9.4 Gastrointestinal Cancer Drugs Product Introduction
  • 10.9.5 Sanofi Recent Development
• 10.10 Novartis AG
  • 10.10.1 Novartis AG Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Gastrointestinal Cancer Drugs
  • 10.10.4 Gastrointestinal Cancer Drugs Product Introduction
  • 10.10.5 Novartis AG Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Gastrointestinal Cancer Drugs Sales Channels
  • 11.2.2 Gastrointestinal Cancer Drugs Distributors
• 11.3 Gastrointestinal Cancer Drugs Customers

12 Market Forecast

• 12.1 Global Gastrointestinal Cancer Drugs Sales and Revenue Forecast 2019-2025
• 12.2 Global Gastrointestinal Cancer Drugs Sales Forecast by Type
• 12.3 Global Gastrointestinal Cancer Drugs Sales Forecast by Application
• 12.4 Gastrointestinal Cancer Drugs Forecast by Regions
  • 12.4.1 Global Gastrointestinal Cancer Drugs Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Gastrointestinal Cancer Drugs Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems.
In 2019, the market size of Gastrointestinal Cancer Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Gastrointestinal Cancer Drugs.

This report studies the global market size of Gastrointestinal Cancer Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Gastrointestinal Cancer Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Amgen Limited & Amgen Ireland Limited
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Johnson & Johnson Private Limited
GlaxoSmithKline plc.
Celgene Corporation
Pfizer Inc.
Sanofi
Novartis AG

Market Segment by Product Type
Oncology
Radiology
Others

Market Segment by Application
Hospitals
Specialized Cancer Treatment Centers
Clinics
Ambulatory Surgical Centers

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Gastrointestinal Cancer Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Gastrointestinal Cancer Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Gastrointestinal Cancer Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025